Enfusion (ENFN) Competitors

Vertex (NASDAQ:VERX) and Enfusion (NYSE:ENFN) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Does the media refer more to VERX or ENFN?

In the previous week, Vertex had 24 more articles in the media than Enfusion. MarketBeat recorded 25 mentions for Vertex and 1 mentions for Enfusion. Enfusion's average media sentiment score of 1.58 beat Vertex's score of 0.88 indicating that Enfusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex	13 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enfusion	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community believe in VERX or ENFN?

Vertex received 40 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 49.50% of users gave Vertex an outperform vote while only 19.61% of users gave Enfusion an outperform vote.

Company	Underperform	Outperform
Vertex	Outperform Votes 50 49.50%	Underperform Votes 51 50.50%
Enfusion	Outperform Votes 10 19.61%	Underperform Votes 41 80.39%

Do analysts recommend VERX or ENFN?

Vertex presently has a consensus price target of $49.82, indicating a potential upside of 40.43%. Enfusion has a consensus price target of $11.83, indicating a potential upside of 6.56%. Given Vertex's stronger consensus rating and higher possible upside, analysts plainly believe Vertex is more favorable than Enfusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.69
Enfusion	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do institutionals & insiders have more ownership in VERX or ENFN?

70.3% of Vertex shares are owned by institutional investors. Comparatively, 81.1% of Enfusion shares are owned by institutional investors. 44.6% of Vertex shares are owned by company insiders. Comparatively, 36.4% of Enfusion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more volatility and risk, VERX or ENFN?

Vertex has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Is VERX or ENFN more profitable?

Vertex has a net margin of 4.73% compared to Enfusion's net margin of 1.70%. Vertex's return on equity of 24.92% beat Enfusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex	4.73%	24.92%	6.65%
Enfusion	1.70%	6.67%	4.86%

Which has preferable earnings and valuation, VERX or ENFN?

Enfusion has lower revenue, but higher earnings than Vertex. Vertex is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex	$666.78M	8.42	-$13.09M	-$0.34	-104.34
Enfusion	$201.61M	7.11	$6.03M	$0.03	370.17

Summary

Vertex beats Enfusion on 13 of the 19 factors compared between the two stocks.